Supplemental 18F-FDG-PET/CT for detection of malignant transformation of IPMN

• Verfasst von: Bicu, Felix [VerfasserIn]
• Verfasst von: Rink, Johann [VerfasserIn]
• Verfasst von: Froelich, Matthias F. [VerfasserIn]
• Verfasst von: Cyran, Clemens Christian Joachim [VerfasserIn]
• Verfasst von: Rübenthaler, Johannes [VerfasserIn]
• Verfasst von: Birgin, Emrullah [VerfasserIn]
• Verfasst von: Röhrich, Manuel [VerfasserIn]
• Verfasst von: Tollens, Fabian [VerfasserIn]
• Titel: Supplemental 18F-FDG-PET/CT for detection of malignant transformation of IPMN
• Titelzusatz: a model-based cost-effectiveness analysis
• Verf.angabe: Felix Bicu, Johann S. Rink, Matthias F. Froelich, Clemens C. Cyran, Johannes Rübenthaler, Emrullah Birgin, Manuel Röhrich and Fabian Tollens
• E-Jahr: 2021
• Jahr: 18 March 2021
• Umfang: 12 S.
• Fussnoten: Im Titel ist "18" hochgestellt ; Gesehen am 31.05.2021
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2021
• Band/Heft Quelle: 13(2021), 6, Artikel-ID 1365, Seite 1-12
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers13061365
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cost-effectiveness
• Sach-SW: IPMN
• Sach-SW: malignancy detection
• Sach-SW: Pancreas lesions
• Sach-SW: PET/CT
• K10plus-PPN: 1759248762

Abstract

Accurate detection of malignant transformation and risk-stratification of intraductal papillary mucinous neoplasms (IPMN) has remained a diagnostic challenge. Preliminary findings have indicated a promising role of positron emission tomography combined with computed tomography and 18F-fluorodeoxyglucose (18F-FDG-PET/CT) in detecting malignant IPMN. Therefore, the aim of this model-based economic evaluation was to analyze whether supplemental FDG-PET/CT could be cost-effective in patients with IPMN. Decision analysis and Markov modeling were applied to simulate patients’ health states across a time frame of 15 years. CT/MRI based imaging was compared to a strategy with supplemental 18F-FDG-PET/CT. Cumulative costs in US-$ and outcomes in quality-adjusted life years (QALY) were computed based on input parameters extracted from recent literature. The stability of the model was evaluated by deterministic sensitivity analyses. In the base-case scenario, the CT/MRI-strategy resulted in cumulative discounted costs of USD $106,424 and 8.37 QALYs, while the strategy with supplemental FDG-PET/CT resulted in costs of USD $104,842 and a cumulative effectiveness of 8.48 QALYs and hence was cost-saving. A minimum specificity of FDG-PET/CT of 71.5% was required for the model to yield superior net monetary benefits compared to CT/MRI. This model-based economic evaluation indicates that supplemental 18F-FDG-PET/CT could have a favorable economic value in the management of IPMN and could be cost-saving in the chosen setting. Prospective studies with standardized protocols for FDG-PET/CT could help to better determine the value of FDG-PET/CT.